{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,2]],"date-time":"2026-01-02T07:50:48Z","timestamp":1767340248096,"version":"build-2065373602"},"reference-count":44,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Dermatologic Clinics"],"published-print":{"date-parts":[[2021,7]]},"DOI":"10.1016\/j.det.2021.03.005","type":"journal-article","created":{"date-parts":[[2021,5,15]],"date-time":"2021-05-15T09:20:52Z","timestamp":1621070452000},"page":"407-415","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":23,"title":["Alopecia Areata"],"prefix":"10.1016","volume":"39","author":[{"given":"Caiwei","family":"Zheng","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonella","family":"Tosti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.det.2021.03.005_bib1","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1038\/jid.2010.427","article-title":"Genetic variants in CTLA4 are strongly associated with alopecia areata","volume":"131","author":"John","year":"2011","journal-title":"J\u00a0Invest Dermatol"},{"issue":"10","key":"10.1016\/j.det.2021.03.005_bib2","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1038\/nri2835","article-title":"Current perspectives of natural killer cell education by MHC class I molecules","volume":"10","author":"H\u00f6glund","year":"2010","journal-title":"Nat Rev Immunol"},{"issue":"16","key":"10.1016\/j.det.2021.03.005_bib3","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1056\/NEJMra1103442","article-title":"Alopecia areata","volume":"366","author":"Gilhar","year":"2012","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.det.2021.03.005_bib4","first-page":"397","article-title":"Epidemiology and burden of alopecia areata: a systematic review","volume":"8","author":"Villasante Fricke","year":"2015","journal-title":"Clin Cosmet Investig Dermatol"},{"key":"10.1016\/j.det.2021.03.005_bib5","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/j.jaad.2009.02.006","article-title":"Concordance rate of alopecia areata in identical twins supports both genetic and environmental factors","volume":"62","author":"Rodriguez","year":"2010","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"2","key":"10.1016\/j.det.2021.03.005_bib6","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.jaad.2009.10.031","article-title":"Alopecia areata update: part II. Treatment","volume":"62","author":"Alkhalifah","year":"2010","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.det.2021.03.005_bib7","doi-asserted-by":"crossref","first-page":"2677","DOI":"10.1038\/jid.2010.180","article-title":"Hair follicles from alopecia areata patients exhibit alterations in immune privilege-associated gene expression in advance of hair loss","volume":"130","author":"Kang","year":"2010","journal-title":"J\u00a0Invest Dermatol"},{"issue":"7302","key":"10.1016\/j.det.2021.03.005_bib8","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1038\/nature09114","article-title":"Genome-wide association study in alopecia areata implicates both innate and adaptive immunity","volume":"466","author":"Petukhova","year":"2010","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.det.2021.03.005_bib9","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1097\/DAD.0b013e318185a66e","article-title":"Investigation of the inflammatory mechanisms in alopecia areata","volume":"31","author":"Cetin","year":"2009","journal-title":"Am J Dermatopathol"},{"key":"10.1016\/j.det.2021.03.005_bib10","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1146\/annurev.immunol.021908.132653","article-title":"Recent advances in the genetics of autoimmune disease","volume":"27","author":"Gregersen","year":"2009","journal-title":"Annu Rev Immunol"},{"issue":"2","key":"10.1016\/j.det.2021.03.005_bib11","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1046\/j.1087-0024.2003.00807.x","article-title":"The hair follicle and immune privilege","volume":"8","author":"Paus","year":"2003","journal-title":"J\u00a0Investig Dermatol Symp Proc"},{"issue":"5","key":"10.1016\/j.det.2021.03.005_bib12","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1038\/sj.jid.5701183","article-title":"Maintenance of hair follicle immune privilege is linked to prevention of NK cell attack","volume":"128","author":"Ito","year":"2008","journal-title":"J\u00a0Invest Dermatol"},{"key":"10.1016\/j.det.2021.03.005_bib13","first-page":"189096","article-title":"CD8+ T-cell deficiency, Epstein-Barr virus infection, vitamin D deficiency, and steps to autoimmunity: a unifying hypothesis","volume":"2012","author":"Pender","year":"2012","journal-title":"Autoimmune Dis"},{"issue":"1","key":"10.1016\/j.det.2021.03.005_bib14","doi-asserted-by":"crossref","first-page":"S12","DOI":"10.1016\/j.jisp.2017.10.014","article-title":"Hair follicle immune privilege revisited: the key to alopecia areata management","volume":"19","author":"Paus","year":"2018","journal-title":"J\u00a0Investig Dermatol Symp Proc"},{"key":"10.1016\/j.det.2021.03.005_bib15","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1242\/jcs.00963","article-title":"The JAK\/STAT signaling pathway","volume":"117","author":"Rawlings","year":"2004","journal-title":"J\u00a0Cell Sci"},{"issue":"12","key":"10.1016\/j.det.2021.03.005_bib16","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1038\/nrd.2017.201","article-title":"JAK inhibition as a therapeutic strategy for immune and inflammatory diseases","volume":"16","author":"Schwartz","year":"2017","journal-title":"Nat Rev Drug Discov"},{"issue":"9","key":"10.1016\/j.det.2021.03.005_bib17","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1038\/nm.3645","article-title":"Alopecia areata is driven by cytotoxic T lymphocytes and is reversed by JAK inhibition","volume":"20","author":"Xing","year":"2014","journal-title":"Nat Med"},{"issue":"15","key":"10.1016\/j.det.2021.03.005_bib18","doi-asserted-by":"crossref","first-page":"e89790","DOI":"10.1172\/jci.insight.89790","article-title":"Oral ruxolitinib induces hair regrowth in patients with moderate-to-severe alopecia areata","volume":"1","author":"Mackay-Wiggan","year":"2016","journal-title":"JCI Insight"},{"issue":"8","key":"10.1016\/j.det.2021.03.005_bib19","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1111\/ijd.13598","article-title":"Two cases of alopecia areata treated with ruxolitinib: a discussion of ideal dosing and laboratory monitoring","volume":"56","author":"Vandiver","year":"2017","journal-title":"Int J Dermatol"},{"issue":"2","key":"10.1016\/j.det.2021.03.005_bib20","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1016\/j.jaad.2018.08.040","article-title":"Ruxolitinib for the treatment of severe alopecia areata","volume":"80","author":"Liu","year":"2019","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"15","key":"10.1016\/j.det.2021.03.005_bib21","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.89776","article-title":"Safety and efficacy of the JAK inhibitor tofacitinib citrate in patients with alopecia areata","volume":"1","author":"Kennedy Crispin","year":"2016","journal-title":"JCI Insight"},{"issue":"1","key":"10.1016\/j.det.2021.03.005_bib22","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.jaad.2016.09.007","article-title":"Tofacitinib for the treatment of severe alopecia areata and variants: a study of 90 patients","volume":"76","author":"Liu","year":"2017","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"2","key":"10.1016\/j.det.2021.03.005_bib23","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1159\/000494613","article-title":"Janus kinase inhibitors for the treatment of severe alopecia areata: an open-label comparative study","volume":"235","author":"Almutairi","year":"2019","journal-title":"Dermatology"},{"issue":"4","key":"10.1016\/j.det.2021.03.005_bib24","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1016\/j.jaad.2016.11.038","article-title":"Experience with oral tofacitinib in 8 adolescent patients with alopecia universalis","volume":"76","author":"Castelo-Soccio","year":"2017","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"2","key":"10.1016\/j.det.2021.03.005_bib25","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1016\/j.jaad.2018.08.041","article-title":"Tofacitinib for the treatment of alopecia areata in preadolescent children","volume":"80","author":"Craiglow","year":"2019","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"4","key":"10.1016\/j.det.2021.03.005_bib26","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/j.ebiom.2015.02.015","article-title":"Reversal of alopecia areata following treatment with the JAK1\/2 inhibitor baricitinib","volume":"2","author":"Jabbari","year":"2015","journal-title":"EBioMedicine"},{"issue":"10","key":"10.1016\/j.det.2021.03.005_bib27","first-page":"892","article-title":"Treatment of severe alopecia areata with baricitinib","volume":"5","author":"Olamiju","year":"2019","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.det.2021.03.005_bib28","doi-asserted-by":"crossref","first-page":"455","DOI":"10.3389\/fphar.2016.00455","article-title":"Curcumin suppressed activation of dendritic cells via JAK\/STAT\/SOCS signal in mice with experimental colitis","volume":"7","author":"Zhao","year":"2016","journal-title":"Front Pharmacol"},{"issue":"6","key":"10.1016\/j.det.2021.03.005_bib29","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1016\/j.jaad.2018.02.031","article-title":"Topical 2% tofacitinib for children with alopecia areata, alopecia totalis, and alopecia universalis","volume":"78","author":"Putterman","year":"2018","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"1","key":"10.1016\/j.det.2021.03.005_bib30","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.jaad.2017.03.024","article-title":"Topical Janus kinase inhibitors for the treatment of pediatric alopecia areata","volume":"77","author":"Bayart","year":"2017","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"12","key":"10.1016\/j.det.2021.03.005_bib31","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1111\/ijd.14192","article-title":"Treatment of alopecia universalis with topical Janus kinase inhibitors: a double blind, placebo, and active controlled pilot study","volume":"57","author":"Bokhari","year":"2018","journal-title":"Int J Dermatol"},{"issue":"6","key":"10.1016\/j.det.2021.03.005_bib32","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1177\/1203475417716363","article-title":"A\u00a0case of topical ruxolitinib treatment failure in alopecia areata","volume":"21","author":"Deeb","year":"2017","journal-title":"J\u00a0Cutan Med Surg"},{"issue":"3","key":"10.1016\/j.det.2021.03.005_bib33","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1016\/j.jaad.2020.09.091","article-title":"An open-label study evaluating the efficacy of abatacept in alopecia areata","volume":"84","author":"Mackay-Wiggan","year":"2021","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"3","key":"10.1016\/j.det.2021.03.005_bib34","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1111\/bjd.12397","article-title":"A\u00a0randomized, double-blind, placebo- and active-controlled, half-head study to evaluate the effects of platelet-rich plasma on alopecia areata","volume":"169","author":"Trink","year":"2013","journal-title":"Br J Dermatol"},{"issue":"7","key":"10.1016\/j.det.2021.03.005_bib35","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1111\/j.1524-4725.2012.02394.x","article-title":"Autologous platelet-rich plasma: a potential therapeutic tool for promoting hair growth","volume":"38","author":"Li","year":"2012","journal-title":"Dermatol Surg"},{"issue":"6","key":"10.1016\/j.det.2021.03.005_bib36","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1097\/01.prs.0000239560.29172.33","article-title":"The role of platelet plasma growth factors in male pattern baldness surgery","volume":"118","author":"Uebel","year":"2006","journal-title":"Plast Reconstr Surg"},{"issue":"4","key":"10.1016\/j.det.2021.03.005_bib37","first-page":"661","article-title":"Platelet-rich plasma: growth factors and pro- and anti-inflammatory properties","volume":"78","author":"El-Sharkawy","year":"2007","journal-title":"J\u00a0Peridontol"},{"key":"10.1016\/j.det.2021.03.005_bib38","first-page":"118","article-title":"Intralesional platelet rich plasma vs intralesional triamcinolone in the treatment of alopecia areata: a comparative study","volume":"4","author":"Shumez","year":"2015","journal-title":"Int J Med Res Health Sci"},{"issue":"1","key":"10.1016\/j.det.2021.03.005_bib39","doi-asserted-by":"crossref","DOI":"10.1111\/dth.12437","article-title":"Platelets rich plasma versus minoxidil 5% in treatment of alopecia areata: a trichoscopic evaluation. LID - 10.1111\/dth.12437 [doi]","volume":"30","author":"El Taieb","year":"2017","journal-title":"Dermatol Ther"},{"key":"10.1016\/j.det.2021.03.005_bib40","first-page":"1473","article-title":"Evaluation of platelet-rich plasma vs intralesional steroid in treatment of alopecia areata. LID - 10.1111\/jocd.12858 [doi]","author":"Albalat","year":"2019","journal-title":"J\u00a0Cosmet Dermatol"},{"issue":"1","key":"10.1016\/j.det.2021.03.005_bib41","first-page":"87","article-title":"Platelet-rich plasma combined with intralesional triamcinolone acetonide for the treatment of alopecia areata: a case report","volume":"20","author":"Mubki","year":"2016","journal-title":"J\u00a0Dermatol Surg"},{"issue":"2","key":"10.1016\/j.det.2021.03.005_bib42","first-page":"534","article-title":"Dual efficacy of dupilumab in a patient with concomitant atopic dermatitis and alopecia areata","volume":"179","author":"Darrigade","year":"2018","journal-title":"Br J Dermatol"},{"issue":"7","key":"10.1016\/j.det.2021.03.005_bib43","doi-asserted-by":"crossref","first-page":"675","DOI":"10.2340\/00015555-3183","article-title":"Dupilumab improved alopecia areata in a patient with atopic dermatitis: a case report","volume":"99","author":"Uchida","year":"2019","journal-title":"Acta Dermatol Venereol"},{"issue":"11","key":"10.1016\/j.det.2021.03.005_bib44","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1001\/jamadermatol.2018.2976","article-title":"Hair regrowth in a patient with long-standing alopecia totalis and atopic dermatitis treated with dupilumab","volume":"154","author":"Penzi","year":"2018","journal-title":"JAMA Dermatol"}],"container-title":["Dermatologic Clinics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S073386352100019X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S073386352100019X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T10:45:44Z","timestamp":1760006744000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S073386352100019X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7]]},"references-count":44,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021,7]]}},"alternative-id":["S073386352100019X"],"URL":"https:\/\/doi.org\/10.1016\/j.det.2021.03.005","relation":{},"ISSN":["0733-8635"],"issn-type":[{"type":"print","value":"0733-8635"}],"subject":[],"published":{"date-parts":[[2021,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Alopecia Areata","name":"articletitle","label":"Article Title"},{"value":"Dermatologic Clinics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.det.2021.03.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}